Selected source guides
381 articles and resources in this section.
- 1955 study in chronic schizophrenia
Original historical paper on clinical and behavioral reactions to LSD.
- 2025 review of psychotic depression
Maps the treatment studies, patient populations, depression outcomes and reported adverse events.
- 2026 review of ketamine and schizophrenia
Discusses symptom overlap, possible benefits and risks, and the lack of published randomized treatment evidence in its search.
- 2026 review of mood disorders with psychosis
Examines how publications described dissociative and psychotic effects during ketamine or esketamine exposure.
- 2026 tobacco crossover study
Compares objective study outcomes and participants’ subjective experiences with an active comparator.
- 5-MeO-DMT clinical pharmacology and safety review
The review discusses transient perceptual disturbances, acute paranoia and reports of psychosis, including some involving additional substances.
- 5-MeO-DMT survey of reported benefits and adverse effects
The paper presents perceived changes separately for respondents who reported different lifetime conditions.
- A clinical approach to diagnosis of autoimmune encephalitis
Graus et al. · 2016 · International diagnostic framework
- A clinical review of the treatment of catatonia
Sienaert et al. · 2014 · Review of early French reports and other treatments
- A controlled investigation of the amobarbital interview
McCall, Shelp & McDonald · 1992 · Randomized blinded comparison in catatonic mutism
- A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
The first pivotal registry record describes the severe-PTSD population and the prespecified clinician-rated primary endpoint.
- A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)
The second pivotal registry record describes the confirmatory study and its moderate-to-severe PTSD population.
- A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders
The registration identifies the two proposed indications and documents withdrawal before any participant enrolled.
- A Phase 2A Trial of DT402 for Autism Spectrum Disorder
The registry confirms the five-person single-group design, completed status and R-MDMA formulation.
- Acute suicidal behavior in a clinical trial · Brazilian Journal of Psychiatry
Describes a serious clinical event after exposure in a separate study.
- Additional recurrence-prevention case
A separate case report examined lithium as maintenance treatment for recurring catatonic stupor.
- Additional signs and information from others
University of Rochester · standardized patient · 7 min 31 sec
- Adjunct ketamine pilot in schizophrenia and depression
The repeated-treatment pilot followed depression, schizophrenia symptom ratings and functional brain measures. The early improvement did not persist.
- Adjunctive cannabidiol trial
Reports a small positive-symptom difference in 88 participants and uncertainty around cognitive and functional outcomes.
- Adolescent depression crossover study
Describes the active comparator, immediate improvement and differences between the depression measures during follow-up.
- Adult encephalitis cohort
The investigators compared adults with and without catatonia and documented immune treatments and medical complications.
- Advances in neurobiological mechanisms
The public page identifies a lecture on catatonia mechanisms and clinical implications. Playback requires sign-in. No claim or story from its unseen recording is included.
- AIDS survivor group-therapy pilot
Reports feasibility and self-rated demoralization over follow-up in a narrowly defined clinical population.
- Alcohol relapse prevention study
Tests short-term abstinence after withdrawal and describes a negative primary comparison.
- Alternative treatment in anti-NMDAR encephalitis catatonia
Wadhwa et al. · 2024 · Adolescent case · DOI 10.1080/13554794.2024.2436214
- Ambien CR prescribing information
U.S. prescribing information · Insomnia indication and safety
- An overview of catatonia
Scott Beach, MD · NAMI Ask the Expert · event March 19, 2026
- Anorexia nervosa feasibility study
Describes selection criteria, monitoring, tolerability and exploratory eating-disorder outcomes.
- Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms
Cochrane examined comparative evidence for antipsychotics in schizophrenia-spectrum conditions with catatonic symptoms. Its reviewers found a small study comparing risperidone…
- Antipsychotics in the treatment of catatonia
This review identified published experiences with antipsychotic treatment in people with catatonia. The accounts include improvement, little change and clinical worsening.
- APA resource document on catatonia
American Psychiatric Association · 2025 · Clinical resource
- APA resource document · alternate supplied URL
Matched to the same APA document · Duplicate retained
- Are we ready to move?
Stephan Heckers, MD, MSc · University of Washington · presented May 16, 2025
- ARISE registry record
Identifies the background medicines, population, randomized design and outcomes.
- ARISE sponsor results
Reports the prespecified primary result in participants who continued their baseline antipsychotic.
- Ascend trial registry record
Defines the independently registered confirmatory study, outcomes and eligibility.
- ASPIRE I
Reports the first phase 3 comparison, including the separate depression and suicidality endpoints.
- ASPIRE II
Replicates the acute depression finding and reports the lack of significant separation on suicidality ratings.
- Australian Therapeutic Goods Administration access guidance
The regulator describes access to unapproved MDMA for PTSD through specifically authorized psychiatrists.
- Ayahuasca and harmful drinking in university students
The article identifies the primary drinking outcome and explicitly reports the effect of statistical correction.
- Ayahuasca trial in treatment-resistant depression
The trial studied a botanical preparation and measured depression severity.
- Ayahuasca-assisted meaning reconstruction for bereavement
Compares three groups and reports grief severity and quality-of-life measures.
- Ayurveda for psychotic disorders
2023 · Systematic review · Different clinical population
- Ayurvedic medicine and product safety
National Center for Complementary and Integrative Health · Public guidance
- Azhari and colleagues
Reports self-rated use and confidence in abstaining during combined behavioral and pharmacological treatment.
- BAP consensus guideline
This guideline follows catatonia from the first observation of a change in movement or speech through investigation, treatment and prevention of physical complications.
- Benzodiazepines in schizophrenia-associated catatonia
Cochrane · 2019 · Systematic review · PMID 31425609
- Bipolar disorder case
The case traces an individual’s recovery of function after several medicines had provided insufficient benefit.
- Blood DMT in schizophrenia and controls
This 1976 study measured an endogenous substance and found no significant group difference.
- Body dysmorphic disorder pilot
Describes the selected participants, symptom trajectories and tolerability after treatment.
- Borderline personality disorder pilot
Reports the primary suicidal-ideation result, secondary functioning assessment and brief dissociative effects.
- BPL-003 alcohol use disorder feasibility study
Reports individual drinking patterns, adherence and adverse events during follow-up.
- BPL-003 depression study · JAMA
The authors describe selection criteria, clinical monitoring and the depression outcomes studied.
- BPL-003 randomized clinical trial · JAMA
Reports the primary 29-day comparison, short-term adverse events and eight weeks of follow-up.
- Brazilian phase 2a depression study
The paper reports changes in depression and suicidal thinking after treatment, with follow-up to three months.
- Bristol Imperial MDMA in Alcoholism Study
The registry describes the open-label alcohol dependence study and follow-up after community detoxification.
- Bristol–Imperial MDMA in Alcoholism study
The publication describes recruitment, tolerability, drinking outcomes and the limits of this first feasibility cohort.
- Bush–Francis Catatonia Rating Scale resources at Rochester
Rochester brings the scale, a training manual and filmed examination examples together. The materials help clinicians compare what a sign looks like with the rules used to…
- Böszörményi and Szára · Historical paper
The authors observed temporary improvement in three people and explicitly considered the additional clinical attention as an alternative explanation. They also documented…
- Caliman-Fontes and colleagues, 2024
This broader review included 25 patients from 20 publications, including reports involving ECT. One person stopped treatment because dissociation was intolerable.
- Calling 911
The US National 911 Program explains how to request emergency help and what information a dispatcher needs.
- Case series of excited catatonia
The report describes the initial emergencies, changes in agitation, other treatments and cardiovascular risks.
- CATATOES protocol
Haroche et al. · 2025 · Sham-controlled tDCS design · PMID 41062970
- Catatonia
Heckers & Walther · NEJM · 2023 · DOI 10.1056/NEJMra2116304
- Catatonia after reported synthetic cannabinoid use
A 32-year-old developed severe catatonia in the setting of reported first-time synthetic cannabinoid use. The treating team described intensive lorazepam treatment and…
- Catatonia and catalepsy
This professional reference discusses catatonia and catalepsy. Catalepsy is a particular examination sign, while catatonia can include changes in speech, activity and other…
- Catatonia during pregnancy and the postpartum period
Csihi et al. · 2024 issue · Systematic literature review
- Catatonia educational reel
Zayed Almadidy · Instagram · caption recorded in the original Atlas review
- Catatonia for patients and carers
Written for people experiencing catatonia and those close to them, this guide describes changes that can be hard to put into words during a consultation.
- Catatonia in an adolescent after ecstasy use
Clinicians describe a 16-year-old with a history of recreational ecstasy use who presented with mutism and immobility.
- Catatonia in older adults
Jaimes-Albornoz et al. · 2022 · Systematic review
- Catatonia in patients with dementia admitted to a geriatric psychiatry ward
Sharma et al. · 2017 · clinical series, Results and Table 1 · PMID 28936082
- Catatonia in psychosis
Sarah Riley, MD · STEP Learning Collaborative · July 28, 2025
- Catatonia in sixty seconds
medschoolbro · medical exam short · January 20, 2026
- Catatonia mnemonics
Memorable Psychiatry and Neurology · June 7, 2022
- Catatonia psychopathology and phenomenology
Dawkins et al. · 2022 · Clinical records and personal accounts
- Catatonia symptoms
Erik Messamore, MD, PhD · SZconsult learning community · August 18, 2020
- Catatonia treatments and risk of recurrence
2026 · Retrospective adult cohort · PMID 41935752
- Catatonia · posturing demonstration
The brief narration describes maintaining a passively placed posture. It illustrates a physical sign without establishing etiology, awareness, treatment or long-term outcome…
- Catatonic stupor after ecstasy — correspondence
A subsequent letter discusses the 1993 report and should not be counted as an independent treatment or replication.
- CDC overview of ketamine and esketamine
Distinguishes anesthetic ketamine and off-label psychiatric uses from the labeled uses of intranasal esketamine.
- Childhood catatonia
Cincinnati Children’s describes the ways a child’s movement, speech, eating and interaction can change. It includes both marked slowing and episodes of increased activity.
- Clinical guideline discussed in this lecture
This guideline follows catatonia from the first observation of a change in movement or speech through investigation, treatment and prevention of physical complications.
- Clinical program outcomes in trauma-exposed veterans
Reports psychiatric symptoms before and after a program that combined two psychedelics.
- ClinicalTrials.gov search for catatonia and MDMA
This search lets readers recheck for newly registered studies in which MDMA is listed as an intervention for catatonia.
- ClinicalTrials.gov · NCT02914769
Lists the Brazilian placebo-controlled study and its depression outcomes.
- ClinicalTrials.gov · NCT04673383
Registry record for the SPL026 development study, which included healthy volunteers and a depression cohort.
- ClinicalTrials.gov · NCT04698603
5-MeO-DMT (mebufotenin) · Treatment-resistant depression
- ClinicalTrials.gov · NCT05553691
A separate completed 18-person study assessed safety with and without ongoing SSRI therapy. No results were posted in this record at review.
- ClinicalTrials.gov · NCT05660642
Earlier BPL-003 open-label study examined safety and symptom change, including participants receiving an SSRI.
- ClinicalTrials.gov · NCT05674929
Protocol for the open-label alcohol use disorder study.
- ClinicalTrials.gov · NCT05800860
5-MeO-DMT (mebufotenin) · Treatment-resistant depression
- ClinicalTrials.gov · NCT05804708
Confirms actual enrollment and explains why recruitment ended early.
- ClinicalTrials.gov · NCT05839509
Confirms the bipolar II population, early termination and six participants.
- ClinicalTrials.gov · NCT05870540
The protocol is for treatment-resistant major depression and lists psychiatric exclusions.
- ClinicalTrials.gov · NCT06051721
Identifies the modified compound, both study groups and the week-six endpoint.
- ClinicalTrials.gov · NCT06070649
Specifies the alcohol-use population and trial outcomes.
- ClinicalTrials.gov · NCT06094907
The registry confirms a completed 14-participant study and describes the outcome measures.
- ClinicalTrials.gov · NCT06150859
Describes eligibility, assignment and the planned outcomes.
- ClinicalTrials.gov · NCT06812221
Lists actual enrollment, eligibility, the clinical measures and the absence of posted registry results.
- ClinicalTrials.gov · NCT06927076
Sets out the separate anesthesia-masking design and planned depression outcome.
- ClinicalTrials.gov · NCT07212946
The separate randomized major depression study compared ayahuasca with esketamine. The registry lists 22 participants and no posted group outcomes.
- ClinicalTrials.gov · NCT07317206
Lists the two interventions, PTSD measures and small target sample.
- ClinicalTrials.gov · NCT07317219
Separate study of body-image perception in healthy participants. No results were posted at review.
- ClinicalTrials.gov · NCT07317232
The record describes the sample, the comparator and symptom measures.
- ClinicalTrials.gov · NCT07562191
Lists the depression and suicidal ideation endpoints, blinded design, target enrollment and study status.
- ClinicalTrials.gov · NCT07717866
Separate observational registry record for a multicomponent program, with no posted trial results.
- ClinicalTrials.gov · NCT07747324
Specifies the functional seizure population and the outcomes under study.
- Closing discussion
This link starts Features and clinical nuance at 59:23, at the passage on closing discussion.
- Clozapine add-on crossover trial
Each treatment period lasted 12 weeks. The authors reported small effects for memory and negative symptoms.
- Clozapine and ketamine challenge
Among ten people with schizophrenia, clozapine attenuated the positive symptoms induced during a ketamine challenge.
- Clozapine prescribing information
The prescribing information explains the cardiovascular risks of resuming clozapine after interrupted treatment.
- COMP360 US application announcement
Documents the sponsor’s application submission and summarizes its pivotal efficacy results.
- Companion description of this recording
The music therapy provider describes neurological rehabilitation and the use of rhythm during walking practice. The clip supplied to the Atlas shows someone practicing after a…
- Comparative effectiveness in Down syndrome regression disorder
Santoro et al. · 2026 · Prospective observational study · PMID 41795763
- Controlled LSD-assisted anxiety therapy trial
Reports anxiety outcomes and tolerability in participants with and without life-threatening illness.
- Current practice and new directions
Jonathan Rogers, MD · CPFT Research · June 7, 2023
- Current principles of motor control, with special reference to vertebrate locomotion
Grillner and El Manira · Physiological Reviews · 2020
- Dawkins and colleagues’ study of patient accounts
This paper examines first-person descriptions of catatonia. It gives context to a common family question about what a person may have experienced while appearing unresponsive.
- Definium SEC filing on Voyage and Panorama
Reports sponsor analyses of the 12-week phase 3 generalized anxiety results and program status.
- Delirium and catatonia in a Lebanese medical consultation service
Chabbouh, Abbas et al. · 2025 · chart review, Table 1 · DOI 10.1186/s12888-025-07646-x
- Delirium and catatonia in critically ill patients
Could delirium and catatonic signs occur in the same critically ill person? The DeCat investigators repeatedly assessed 136 patients in intensive care for features of both…
- Diagnosis, treatment and pathophysiology
Joan Striebel, MD, with Andy Cutler, MD · NEI Podcast E234 · September 18, 2024
- DIAMOND phase 3 results
The sponsors report that both trials missed the prespecified primary endpoint.
- DMT-associated psychosis · Clinical case report
The authors describe psychosis following repeated exposure, relevant when weighing potential harm.
- Early GH001 phase 1/2 study
The early uncontrolled trial included 16 people, preceding the larger placebo-controlled phase 2b trial.
- Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial
This separate feasibility study enrolls people with severe chronic neuropathic pain.
- ECT compared with risperidone after limited response to lorazepam
Girish and Gill · 2003 · randomized study · PMID 21206808
- ECT for catatonia of non-psychiatric origins
Andrew Mumma and Carey Meyers · Thomas Jefferson University · March 23, 2022
- ECT for patients with catatonia
Lloyd et al. · 2020 · Clinical review · PMID 33061390
- ECT in Down syndrome regression disorder
The five-patient institutional series identifies when clinicians used ketamine before placing an IV.
- Electroconvulsive therapy
Royal College of Psychiatrists · Family information
- Electroconvulsive therapy in MDMA-associated psychosis and catatonic features
The authors discuss diagnostic uncertainty, including possible underlying bipolar illness, during the clinical course.
- ELEKT-D outcomes
Reports the acute comparison of ketamine infusions and ECT, including response rates and the prespecified comparison.
- ELEKT-D protocol
Provides eligibility, interventions, primary outcome and trial history.
- Emotion regulation in a community sample with borderline traits
Reports exploratory symptom and mindfulness measures and a subgroup selected by screening scores.
- EMPOWER 1 and 2 results
AbbVie reports both negative primary results and gives symptom changes by treatment arm.
- English NHS feasibility trial
A separate 60-person study assessed feasibility and observed a short-term depression-score advantage in a secondary analysis.
- ENIGMA-TRS 1 enrollment announcement
Describes the randomized trial, enrollment, 12-week endpoint and the separate ENIGMA-TRS 2 program.
- Episode guide and selected references
The Psychiatry Boot Camp page organizes its conversation with Mark Oldham about clinical descriptions of catatonia, including repeated actions, facial expressions and forms of…
- EPISODE randomized clinical trial
Reports the prespecified response analysis, secondary symptom outcomes and safety findings in treatment-resistant depression.
- Esketamine following childbirth
Specifies prenatal symptom eligibility, diagnostic interviews at day 42, event counts and adverse effects.
- Esketamine monotherapy trial
Reports the randomized, double-blind comparison with placebo in adults whose depression had responded inadequately to at least two antidepressants.
- European trial registration
The European record identifies the Norwegian feasibility protocol and its prospectively specified objectives.
- Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury
The registration describes a target of 60 and lists symptom and mechanistic measures.
- Experiences along the continuum of eating disorder recovery
Qualitative interviews document the participants’ perspectives, including the context of ceremonial use.
- Exploratory eating-symptom analysis from MAPP1
This secondary publication examines eating attitudes in the same PTSD sample enrolled in the MAPP1 trial.
- Exploratory OCD study
Describes trial phases and how investigators defined response and remission on the Yale-Brown scale.
- FDA clozapine safety information
FDA explains why blood-count monitoring remains important for detecting severe neutropenia.
- FDA complete response letter
The regulator explained why the submitted evidence was insufficient for US approval, including difficulties with masking and adverse-event assessment.
- FDA methylphenidate label
The US label describes potential exacerbation of psychosis and induction of manic or mixed episodes.
- FDA prescribing information
Specifies the US adult schizophrenia indication, pharmacology, contraindications and adverse reactions.
- FDA prescribing information for Spravato
Specifies approved U.S. indications, supervised administration and monitoring for sedation, dissociation, breathing problems, blood-pressure changes, misuse and abuse.
- Feasibility study of depression and anxiety in cancer care
This 2026 report tracks depression and anxiety with three symptom scales and follows patients for up to three months.
- Features and clinical nuance
Oldham uses examples to distinguish mannerisms, stereotypies, grimacing, agitation and echo phenomena. The discussion moves from a single observed behavior to a pattern over…
- Feder and colleagues
Reports the two-week PTSD outcome in 30 participants and follow-up among responders.
- Five-year functional outcomes after psychiatric admission
Zhang et al. · 2026 · follow-up cohort · PMID 41499902 · abstract and publisher summaries
- Four cases of persistent catatonia
The case series describes prior unsuccessful treatment, the four outcomes and the circumstances of relapse in one patient.
- From the screening items to the wider scale
University of Rochester · standardized patient · 7 min 31 sec
- Functional neuroimaging in catatonia
The review identified functional imaging studies implicating several networks that help organize movements, emotions and behavior. The most extensively studied participants…
- GH001 depression trial · JAMA Psychiatry
Reports a depression outcome and identifies the enrolled population.
- GH001 postpartum depression study
Reports baseline severity, the day-eight outcome and maternal adverse events.
- Going into hospital with a learning disability
NHS · Patient guide to adjustments and hospital passports
- Goldstone Psychiatry & Neuromodulation Center
The supplied Houston listing advertises transcranial magnetic stimulation for depression. The available listing does not establish a catatonia program.
- Gregor and Zheng, 2023
Full account of the initial response, readmission, treatment changes and functional recovery.
- Gómez-Revuelta and colleagues, 2024
Spanish case report describing intranasal esketamine for persistent catatonia in major depression.
- Helus Pharma · Phase 2 topline results
The sponsor describes the six-week finding and labels the six-month observations as pooled.
- Herb–drug interactions
NCCIH reviews interactions between named herbal products and medicines. For some combinations it reports observations from people. For others, the concern rests on laboratory…
- Historical report of DMT experiments in patients with psychosis
The 1958 report documents research exposure in a psychiatric population.
- Hospital chaplaincy and spiritual care
NHS England · Pastoral, spiritual and religious support
- How the conversation is organized
This link starts Features and clinical nuance at 0:00, at the passage on how the conversation is organized.
- How the diagnosis developed
This link starts Features and clinical nuance at 10:33, at the passage on how the diagnosis developed.
- Hyponatraemia and catatonic stupor after taking ecstasy
The original BMJ case report describes stupor alongside a potentially serious metabolic disturbance.
- Initial report of three individuals
The authors describe responses across several domains, including visual-motor functioning, and changes over follow-up.
- Integrating young adults into adult health care
Got Transition · Six Core Elements 3.0 · Transfer package and emergency care plan
- International Society for Bipolar Disorders · 2026 conference abstracts
The GH001 bipolar II abstract reports the mean change in depressive symptoms.
- Interpreting a urine THC metabolite result
American College of Medical Toxicology · 2020 · Position statement
- Interpreting restless activity
This link starts Features and clinical nuance at 36:20, at the passage on interpreting restless activity.
- Introduction and permission for examination
University of Rochester · standardized patient · 7 min 31 sec
- Is ECT an evidence-based treatment for catatonia?
Leroy et al. · 2018 · Systematic review · PMID 28639007
- Iserson and Durga, 2020
Emergency department report describing the examination, return of speech and subsequent psychiatric assessment.
- Johns Hopkins cancer-related distress trial
Describes the second randomized crossover study and longer-term observations in 51 participants.
- Joint clinical practice guideline on benzodiazepine tapering
ASAM and partner societies · 2025 · General adult tapering guidance
- KARMA-Dep 2
Gives the 2025 results for serial infusions alongside inpatient care and reports the confidence interval for the primary outcome.
- Ketamine alongside mindfulness-based relapse prevention
Describes the 55-person trial, abstinence endpoint, relapse analysis and concurrent treatment.
- Ketamine and relapse prevention trial
Distinguishes the percentage of days abstinent from confirmed relapse and reports both at six months.
- KETIS acute-care trial
Defines remission of suicidal ideas, reports outcomes by diagnosis and describes exclusion criteria.
- Kobayashi and colleagues, 2021
Original clinical narrative about ketamine for an acute episode and the patient’s subsequent course.
- Laborit in the historical EU Clinical Trials Register
EudraCT 2021-004049-19 · Netherlands · registry entry
- Laborit randomized trial protocol and outcome definitions
Bot et al. · 2025 · JMIR Research Protocols · Table 1 and Outcome Measures
- Laborit registry record and outcome definitions
ISRCTN11236443 · study record, PDF · primary and secondary outcomes
- Laborit study team and contact
Amsterdam academic psychiatry network · study information
- Laborit trial protocol
2025 · Prospective cohort with embedded randomized comparison
- Lahti and colleagues, 2001
Compares the brief symptom changes following ketamine exposure in volunteers with and without schizophrenia.
- Larger parallel-group trial
The larger trial assessed total schizophrenia symptom severity and found no benefit on its primary endpoint.
- Levodopa in catatonic stupor
An early clinical report documents use of a dopamine precursor in a patient with stupor.
- Listen for conversational and repeated speech
University of Rochester · standardized patient · 7 min 31 sec
- Long-term anxiety follow-up
Tracks participants after the original study and explains the limits of longer-term comparisons.
- Long-term lamotrigine case
The authors describe changes in recurrence and severity during follow-up in a patient with periodic catatonia.
- Lorazepam and catatonic signs in Ugandan children with nodding syndrome
Kakooza-Mwesige et al. · 2015 · uncontrolled pilot, Methods and Figure 2a · PMID 26710961
- Lorazepam challenge in pediatric catatonia
Luccarelli et al. · 2024 · Multisite retrospective cohort · PMID 38986388
- Lorazepam for persistent catatonic signs in stable schizophrenia
Ungvari et al. · 1999 · randomized double-blind crossover study · PMID 10229064
- Lorazepam in suspected neuroleptic-induced catatonia
In 1983, clinicians described four patients whose catatonic reactions they believed were related to antipsychotic treatment. They reported rapid reversal after intravenous…
- Maintenance ECT during COVID-19 service disruptions
Ghaziuddin et al. · 2021 · Observational series in an established maintenance clinic
- Malignant catatonia clinical course
The case describes the change between excitement and stupor and the combined treatment during recovery.
- Mania following ayahuasca consumption · Clinical case
A psychiatric team describes a manic presentation following exposure and discusses prior bipolar vulnerability.
- MAPP1 phase 3 results
This trial reports short-term changes in PTSD symptom severity and functional impairment in severe PTSD.
- MAPP2 confirmatory trial
The publication gives symptom and functional outcomes, adverse events and masking assessments in the second pivotal trial.
- MAPS statement on the reported 2026 resubmission
The research nonprofit responded to external reporting of a new submission. This statement does not document an FDA approval.
- MDMA Assisted Therapy for BN
The protocol describes the three groups, adaptations for bulimia and the prespecified binge-eating endpoint.
- MDMA for AUD/PTSD Comorbidity
The Providence study record specifies alcohol consumption outcomes alongside PTSD measures.
- MDMA for Co-occurring PTSD and OUD After Childbirth
The study record identifies the postpartum population, an estimated enrollment of 15 and the PTSD endpoint.
- MDMA in Borderline Personality Disorder
The protocol specifies social cognition as its primary measure and describes the small single-group design.
- MDMA-Assisted CBCT for PTSD vs CBCT RCT
This separate trial studies how adding MDMA to conjoint PTSD therapy affects clinical and relationship outcomes.
- MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
The prespecified comparison and clinician-rated OCD endpoint are available in the trial record.
- MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
The registry describes the original conjoint-therapy feasibility pilot.
- MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder
The Sydney protocol combines prolonged exposure therapy with the study intervention for participants with both diagnoses.
- MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
The registry identifies the primary anxiety endpoint and the timing of the blinded comparison.
- MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
The study record describes the cancer population, participation by a concerned significant other and the relationship and symptom outcomes.
- MDMA-assisted Therapy for Fibromyalgia
This separate study measures pain severity and interference in people with fibromyalgia.
- MDMA-assisted therapy for major depressive disorder
The original Norwegian pilot reports feasibility, adverse events and depression scores during short-term follow-up.
- MDMA-Assisted Therapy for Mental Healthcare Providers
This separate protocol measures well-being in mental healthcare providers using the Mental Health Continuum scale.
- MDMA-Assisted Therapy for Pathological Narcissism
The study lists actual enrollment, outcome instruments and follow-up for the therapy cohort.
- MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders
This protocol follows healthcare workers and first responders with stress disorders and tracks trauma-related symptoms.
- MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder
This separate VA trial targets 80 veterans and uses randomized assignment to test the combined treatment.
- MDMA-facilitated cognitive-behavioral conjoint therapy for PTSD
The authors describe the couples treated and report both partner- and patient-reported outcomes.
- Medical complications of catatonia and neuroleptic malignant syndrome
Daneshvari et al. · November 2026 · Systematic review · PMID 42998708
- Meet the guest
This link starts Features and clinical nuance at 3:16, at the passage on meet the guest.
- Meta-analysis of six historical trials
Examines short- and longer-term outcomes across randomized alcohol treatment studies.
- Military and veteran PTSD trial
Reports the negative primary PTSD comparison alongside the secondary depression finding.
- Modulation of movement by the basal ganglia
Purves and colleagues · Neuroscience, second edition · 2001
- Movement findings in three patients
Motor ratings and signs of catatonia improved during treatment in three people with acute akinetic catatonia.
- MPATHY Australian trial protocol
The Australian protocol describes a controlled test of MDMA-assisted prolonged exposure for co-occurring PTSD and alcohol use disorder.
- Multicenter encephalitis treatment cohort
The study relates first- and second-line immune treatment to functional outcomes in anti-NMDA receptor encephalitis.
- Muscle tone and reflex assessment
University of Rochester · standardized patient · 7 min 31 sec
- Music as a psychotherapeutic tool in a historical case
This indexed 1963 article shows that clinicians were discussing music in a catatonia-related psychotherapeutic setting decades ago. The catalogue preserves the author…
- Music during an adolescent’s catatonic episode
Lehman et al. · American Psychiatric Association 2021 meeting · Poster 94
- Musicoterapia en una paciente con esquizofrenia catatónica
Ferrari, Boro & Reilly · VI CLAM 2016 proceedings · Spanish · Printed p. 157
- Naturalistic survey of 5-MeO-DMT and mood symptoms
Self-selected respondents described changes in anxiety and depression after group use. Retrospective reports cannot determine causality.
- Neuroanatomy of the corticospinal tract
Munakomi, Reddy and Bordoni · StatPearls · revised 2026
- Neuroanatomy of the spinal cord
The cord has expanded regions serving the limbs. The upper enlargement supplies nerve networks for the arm and hand. Lower cord segments supply the leg and foot.
- Neuroleptic-related catatonia in systemic lupus
Baptista & Choucha · 2019 · Case report · PMID 31433339
- Nine-year follow-up
The paper describes the patient’s earlier cycling, remission during treatment, toxicity and illness after discontinuation.
- Non-invasive brain stimulation for treating catatonia
This review examines reports of non-invasive brain stimulation in catatonia, including stimulation approaches that differ in their targets and mechanisms.
- Nonconvulsive status epilepticus presenting with catatonia
Nonconvulsive status epilepticus is ongoing seizure activity that can be hard to recognize from outward behaviour. This review examines published instances in which people had…
- NYU cancer-related distress trial
Reports clinical symptoms before crossover and after follow-up in 29 participants.
- Observational study in a Canadian First Nations community
Twelve participants joined group counseling and ceremonial sessions. Self-reported problem cocaine use declined significantly. Cannabis and opiate use did not decline.
- Observe movement before speaking
University of Rochester · standardized patient · 7 min 31 sec
- Olazabal Eizaguirre and colleagues, 2016
Spanish case report of chronic catatonia and psychotic depression following an inadequate response to ECT.
- Oldham on definitions of catatonic signs
Oldham compares the ways diagnostic systems and rating instruments describe catatonic features. The terminology can change which observations are counted together.
- Oldham’s clinical work
This link starts Features and clinical nuance at 3:48, at the passage on oldham’s clinical work.
- Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
The registry describes the parent open-label PTSD study that supplied the exploratory pain data.
- Open-label bipolar II study
Reports trajectories of depression and describes the psychiatric adverse events observed with follow-up.
- Original podcast and resources
The publisher’s page for NEI episode 234 identifies the speaker and organizes the original conversation about catatonia, its treatment and possible mechanisms.
- Orsini and colleagues, 2026
Reports the randomized acute-phase outcome and monitoring for mood elevation.
- Other features of the clinical examination
This link starts Features and clinical nuance at 42:55, at the passage on other features of the clinical examination.
- Ovarian teratoma-associated encephalitis
Amorim & McDade · 2016 · Case report · PMID 26964475
- Pain and disability in an open-label PTSD trial
The researchers analyzed a secondary pain measure and reported the change separately by initial pain severity.
- Paper proposing the fear-response hypothesis
Moskowitz proposes that some features of catatonia might be understood through comparison with defensive immobility under threat.
- Participating center’s trial description
Children’s Hospital Los Angeles explains the open-label design and the three interventions for families.
- Patterns of motor activity
This link starts Features and clinical nuance at 51:50, at the passage on patterns of motor activity.
- Pediatric catatonia clinical pathway
Vanderbilt University Medical Center · Local pathway
- Pediatric catatonia review
Researchers rescored published pediatric presentations for catatonic signs and reviewed the sequence of treatments and recovery.
- Pediatric pathway in acute medical settings
Samsel et al. · 2026 · Delphi consensus · PMID 41865798
- Persistent psychosis and medical complications after ecstasy
A case report describes psychiatric and medical illness after an alleged single ingestion of an ecstasy tablet.
- Persistent psychosis following a single ingestion of ecstasy
A separate patient report documents a prolonged course after reported recreational exposure.
- Phase 1 safety and pharmacology study
The authors distinguish self-reported symptoms from a formal diagnosis and report short-term tolerability.
- Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
The protocol describes the social-anxiety eligibility requirements and the psychotherapy and placebo comparison.
- Pilot in veterans with PTSD and their partners
Eight veteran–partner pairs participated in a separate open-label study that reported relationship, PTSD and safety outcomes.
- Pilot outcomes in veterans with PTSD and alcohol use disorder
The authors report completion, PTSD severity and several drinking measures after the open-label intervention.
- Pilot trial of anxiety related to life-threatening illness
The authors give group changes in trait anxiety, the primary statistical comparison and secondary outcomes.
- Placebo-controlled adult ADHD trial
Describes the randomized design and improvement in both groups without between-group superiority.
- Placebo-controlled major depression trial
Describes depression outcomes, disability measures, eligibility and adverse events after randomized assignment.
- Pooled EMERGENT trial analysis
Combines three placebo-controlled trials and quantifies the five-week difference in overall symptom scores.
- Preventing common medical complications of catatonia
Clinebell et al. · 2014 · Literature review and case
- Prospective alcohol and PTSD follow-up in veterans
The investigators describe the drinking-risk subgroup and follow-up through six months.
- Prospective case series in combat veterans
The authors collected checklist scores, daily ratings and interviews and report some adverse acute experiences.
- Prospective nine-patient series
Investigators documented response to a lorazepam challenge before assessing subsequent improvement on carbamazepine.
- Psilocybin and heavy drinking days
Reports the controlled 32-week comparison in people receiving psychotherapy.
- Psilocybin in cocaine use disorder
Reports 180-day outcomes for abstinent days, continuous abstinence and time to first lapse.
- Psychosis after ayahuasca · Case and follow-up
The report describes assessment, antipsychotic treatment and follow-up after a psychotic episode.
- Psychosis with catatonic features after repeated use
Details psychiatric and substance-use risk factors alongside repeated psilocybin exposure.
- PTSD with secondary psychotic features
Bonomo, Huang & Schoenbachler · 2023 · Case report · PMID 37069546
- Published CONNEX phase 3 program
Reports individual and pooled findings from the three 26-week randomized trials.
- Published correction to the veterans case series
Read the correction together with the paper when interpreting its sample and outcome figures.
- Published opening transcript excerpt
This third-party excerpt covers the opening portion of a teaching video about recognizing catatonia with a mnemonic.
- Published phase 2b generalized anxiety trial
Reports changes in anxiety ratings and adverse events in 198 randomized adults.
- Published PTSD open-label study
Reports tolerability and exploratory changes in PTSD symptoms among 22 participants.
- Randomized early schizophrenia trial
Reports the four-week placebo comparison on a schizophrenia symptom scale.
- Randomized ketamine psychotherapy study
Compared two active ketamine regimens alongside psychotherapy after heroin detoxification.
- Randomized pilot in autistic adults
The full report gives Liebowitz Social Anxiety Scale outcomes, follow-up data and the individual trajectories of this small group.
- Randomized wait-list trial in social anxiety disorder
The 2026 report describes clinical outcomes, functional measures and tolerability in the broader social-anxiety population.
- Read the full transcript at NAMI
NAMI provides the public text of its catatonia presentation. Readers can revisit the speaker’s contrasting examples of stillness, repetitive activity and changes during…
- Recognizing malignant illness
This link starts Features and clinical nuance at 55:30, at the passage on recognizing malignant illness.
- Recognizing medical emergencies
MedlinePlus Medical Encyclopedia · emergency warning signs
- Recognizing sustained facial expressions
This link starts Features and clinical nuance at 37:52, at the passage on recognizing sustained facial expressions.
- Recognizing the syndrome
This link starts Features and clinical nuance at 14:27, at the passage on recognizing the syndrome.
- Redefine controlled PTSD trial
Lists eligibility, comparator and outcome measures for the subsequent PTSD trial.
- Registry for the 138-person trial
The trial record gives the primary outcome, actual enrollment and study dates for MEM-MD-29.
- Repeat-session follow-up trial
Compared a course with additional sessions against a single-session strategy and reported abstinence at one year.
- Repeated movement patterns
This link starts Features and clinical nuance at 34:42, at the passage on repeated movement patterns.
- Repeating speech and copying movement
This link starts Features and clinical nuance at 39:45, at the passage on repeating speech and copying movement.
- Residential eating-disorder case series
Describes the participants, intensive co-treatment and brief mood and anxiety follow-up.
- Resonant Light Technology
This manufacturer presents frequency-related products, including PERL and ProGen 3, alongside customer testimonials. The page records what the company sells and how it…
- Resting-state hyperperfusion of the supplementary motor area in catatonia
Walther and colleagues · Schizophrenia Bulletin · 2017
- Retreat study of inattention, hyperactivity and impulsivity
Describes the sample, the adult ADHD symptom questionnaire and assessments before and after the retreat.
- Review of psychostimulant case reports
The review catalogues published clinical experience, the agents used and the limited ability of cases to establish efficacy.
- Review of withdrawal catatonia
Lander, Bastiampillai & Sareen · 2018 · Review of published cases
- Review of withdrawal catatonia
The authors distinguish catatonia following clozapine withdrawal from cases associated with stopping benzodiazepines.
- Rhythm-assisted gait training after stroke
The publisher identifies a stroke survivor receiving neurologic music therapy for gait training. Rhythmic cues accompany walking practice. The population and outcome here…
- Rochester BFCRS teaching collection
Rochester’s teaching collection makes the Bush–Francis examination observable. The videos use standardized patients and let learners compare an examination with worked scoring…
- Rochester teaching example of posturing and catalepsy
This teaching demonstration helps readers distinguish maintaining a posture spontaneously from maintaining a position introduced during an examination.
- Rochester training manual and scoring guide
The Rochester manual explains how examiners observe, elicit and score the individual Bush–Francis signs.
- Rochester’s normal BFCRS examination
University of Rochester · standardized patient · 7 min 31 sec
- Rodriguez and colleagues
Explains the carryover effect, the first-period analysis and how OCD response was defined.
- Rogers and colleagues’ case-control study
Rogers and colleagues searched clinical records for validated diagnoses and compared psychiatric inpatients with and without catatonia. They examined demographic, clinical and…
- Saline-controlled tobacco pilot
Describes withdrawal, craving and smoking behavior over short-term follow-up.
- Sarma and colleagues, 2023
Full case histories, rating scales and follow-up for both Australian patients.
- Secondary analysis of suicidal thinking in depression
Analyzes one symptom domain in the same small randomized depression cohort.
- Separate ACLP clinical teaching guide
The consultation-liaison psychiatry teaching guide gives the clinical context for a learner encountering suspected catatonia in hospital.
- Separate public interview with Georg Northoff
The foundation hosts a separate conversation with Georg Northoff on catatonia research. This gives readers a public route to the researcher’s work alongside a lecture whose…
- Separate randomized trial registry
This record describes the three-arm randomized trial. The cohort numbers and outcomes above come from the separate observational publication.
- Session outline and training results
The workshop program describes a teaching intervention and reports what learners recognized before training. It supplies context for the recording about identifying catatonic…
- Seven-month follow-up in major depressive disorder
The investigators reassessed the original participants to examine the longer-term course of depressive symptoms.
- Severe catatonia case report
The authors describe severe motor and behavioral signs, earlier treatments and the response during hospitalization.
- Six-month smoking cessation trial
Provides verified abstinence outcomes, details of behavioral support and limitations of this pilot comparison.
- Social anxiety and self-perceived public speaking
Reports perceptual, anxiety and bodily-symptom outcomes separately.
- Social anxiety crossover trial
Reports both clinician-led and self-rated anxiety outcomes following ketamine and saline.
- Social Anxiety MDMA-Assisted Therapy Investigation
The registered trial uses immediate and delayed treatment groups to compare changes in social anxiety.
- Sodium oxybate prescribing information
U.S. Food and Drug Administration · CNS depressant warnings
- SPL026 depression trial · Nature Medicine
The actual target and primary outcome were major depression and depression severity.
- Sponsor disclosure of exploratory findings
The sponsor describes its interpretation of outcomes in a securities filing, rather than a peer-reviewed controlled comparison.
- Sponsor financial disclosure · SEC
The filing explicitly identifies the statistically significant comparison as within subject.
- Sponsor messages
This link starts Features and clinical nuance at 1:42, at the passage on sponsor messages.
- Stanford study description
Stanford describes participant eligibility, the comparison groups and the study’s focus on OCD symptoms.
- Stroke and low blood sodium case series
The authors trace symptoms, treatment and recovery in three cases of medically associated catatonia.
- Structural and dynamic mechanisms of GABA-A receptor modulators
Researchers examined the GABA-A receptor bound to zolpidem and to a modulator called DMCM. Their structures show how compounds acting at shared sites can have different…
- Subsequent schizophrenia trial
Describes a later placebo-controlled trial in acute schizophrenia.
- Supervised schizoaffective case report
Distinguishes the symptoms present before psilocybin from the earlier positive symptoms that responded to antipsychotic treatment.
- Syndrome catatonique · French national diagnosis and care protocol
DéfiScience rare-disease network · 2021 · French-language clinical protocol hosted by Haute Autorité de santé
- Systematic review of clozapine in catatonia
The review describes diagnoses, additional treatments and responses across 182 published cases.
- Systematic review of psychedelic-induced psychosis
Summarizes historical schizophrenia studies, including communication changes and agitation, and reviews the quality of evidence.
- Systematic review of symptoms and functioning in PTSD
The review separates each outcome and describes limitations from masking, small studies and differences in psychotherapy.
- Takiwasi addiction treatment outcomes at one year
Describes addiction severity, follow-up completeness and the other elements of the residential program.
- The diagnosis and treatment of catatonia
Rogers, Zandi & David · 2023 · Clinical guideline summary
- The effect of benzodiazepines on catatonia
2026 · Systematic review and meta-analysis · PMID 42009596
- The premotor cortex
Purves and colleagues · Neuroscience, second edition · 2001
- The scariest psychiatric syndrome
The presenter starts with historical images, describes the range of motor signs and malignant illness, then explores fear and an evolutionary account of freezing. The latter…
- The use of zolpidem in catatonia
Yakubu, Gibson & Smit · 2024 · Case report · PMID 39669822
- Think you know how to spot catatonia?
Andrew Francis, Joshua Wortzel, Mark Oldham and Jo Ellen Wilson · ACLP annual meeting, 2021
- Timed transcript excerpt for the later E267 re-release
This timed text belongs to the later re-release of the NEI interview. It helps locate parts of the conversation about diagnosis and treatment.
- Tolerability of MDMA in Schizophrenia
The protocol specifies safety thresholds for worsening positive symptoms, the enrollment target and eligibility criteria.
- Transition from inpatient mental health care
NICE NG53 · Discharge and return to education guidance for England
- Treatment of catatonia with zolpidem
Peglow, Prem & McDaniel · 2013 · Case report · PMID 24026726
- Treatment-resistant anxiety study
Examines the duration of anxiety changes in people without current depression, with midazolam as a control.
- Treatments of catatonia through history
Shorter and Fink · The Madness of Fear · Historical account
- Trejos Orozco and colleagues, 2022
Original case report about psychotic depression, cardiovascular disease and risk of starvation.
- Trial of cognition and symptoms
Reports a second placebo-controlled study with no meaningful benefit and more sedation in the CBD group.
- Twelve-week bipolar depression follow-up
Tracks longer-term mood and tolerability in people who had already benefited from ketamine.
- UCLA study description
The study team explains the rationale for studying social motivation in a selected group of people with stable illness.
- University of Washington grand rounds archive
The University of Washington maintains an archive of psychiatry grand rounds. The listing supplies institutional context for Stephan Heckers’ lecture on recognizing catatonia.
- Unusual versions of familiar movements
This link starts Features and clinical nuance at 31:13, at the passage on unusual versions of familiar movements.
- US sodium oxybate prescribing information
The label explains risks from sedation, respiratory depression and interactions with other depressants.
- VA announcement of its randomized PTSD and alcohol use disorder trial
The Veterans Affairs study plans to compare MDMA-assisted therapy with the same psychotherapy and an active comparator.
- Validation of the Pediatric Catatonia Rating Scale
Benarous et al. · 2016 · Inpatient instrument validation
- van der Meer and colleagues, 2025
Searched 14 databases through February 2025 and excluded ketamine given for anesthesia. The table identifies each person, underlying diagnosis, intervention and follow-up.
- Vienna trial in the EU Clinical Trials Information System
Official study record for ketamine in schizophrenia, including the medicinal product esketamine and its intended symptom targets.
- Voice, speech, and language
National Institute on Deafness and Other Communication Disorders · 2023
- What happens after the arm is released
University of Rochester · standardized patient · 7 min 31 sec
- What the term catatonia describes
This link starts Features and clinical nuance at 4:16, at the passage on what the term catatonia describes.
- When to call 999
The NHS explains when to call 999 for a life-threatening emergency and what happens when the emergency operator answers.
- Why Oldham began studying it
This link starts Features and clinical nuance at 4:55, at the passage on why Oldham began studying it.
- Workplace health and return after long-term sickness absence
NICE NG146 · General return-to-work planning guidance for England
- Yale exploratory study · Major depression and healthy volunteers
An earlier open-label study found a 4.5-point decrease on the 17-item Hamilton depression scale the day after treatment, compared with baseline.
- Yale program listing
The dated Yale STEP Learning Collaborative listing identifies the educational event connected with the catatonia recording.
- Yale School of Medicine · DMT and alcohol use
The investigators describe the therapeutic question and the accompanying psychotherapy.
- Yale STEP provider education
The Yale STEP program gathers educational material for clinicians working in early psychosis. Its teaching collection gives context for the supplied presentation on catatonia.
- Zolpidem for the management of catatonia
Gunther, Tran & Jiang · 2025 issue, online 2024 · PMID 39522949
- Zolpidem in an older patient with resistant catatonia
Wendt et al. · 2023 · Case report · PMID 37711409
- Zolpidem in the diagnosis and treatment of catatonia
Ahuja et al. · September 2026 · Systematic review of cases · PMID 43034532
- Zolpidem in treatment-resistant adolescent catatonia
Two adolescents with persistent catatonic signs showed marked improvement within days of starting zolpidem after prior medication had provided insufficient relief.